Guide — Renal · Pharmacology
Nephrotoxic Medications Nursing Guide
Mechanism, risk factors, monitoring parameters, and AKI prevention strategies for the major nephrotoxic medication classes — NSAIDs, aminoglycosides, contrast agents, ACE inhibitors, vancomycin, cisplatin, and calcineurin inhibitors.
10 min read · Renal · Pharmacology
Educational use only. Drug dosing and monitoring are provider-directed and institutional-protocol specific. Nursing role: recognize risk, monitor, and communicate early. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
Why Nephrotoxicity Matters
Drug-induced AKI accounts for 20–25% of hospital-acquired AKI. The kidney is particularly vulnerable due to high blood flow (20–25% of cardiac output), high metabolic activity, and concentration of drugs in tubular cells during reabsorption. Early recognition of rising creatinine or falling urine output is critical — renal injury is often reversible if the offending agent is stopped promptly.
Nephrotoxic Medication Classes
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
Examples: Ibuprofen, naproxen, ketorolac (Toradol), celecoxib, indomethacin
| Mechanism | NSAIDs block prostaglandin synthesis → prostaglandins normally dilate the afferent arteriole. Without prostaglandins, afferent vasoconstriction → decreased GFR → prerenal AKI. With long-term use: interstitial nephritis, membranous nephropathy, analgesic nephropathy. |
| Risk Factors | Volume depletion, age > 65, CKD (eGFR < 60), heart failure, cirrhosis, concurrent ACE inhibitors or diuretics, high doses |
| Monitoring | Serum creatinine before and 3–7 days after starting. Monitor BUN/Cr. Urine output. Watch for edema (fluid retention). |
| Prevention | Ensure adequate hydration before use. Avoid in high-risk patients. Use lowest effective dose for shortest duration. Prefer acetaminophen when possible. |
| Nursing Notes | Patient education: avoid OTC NSAIDs if on ACE inhibitor/diuretic. Teach that 'ibuprofen is safe' misconception is dangerous in high-risk patients. Hold before procedures requiring contrast. |
| NCLEX Pearl | NSAIDs + dehydration + ACE inhibitor = high AKI risk. Always check hydration status before giving ketorolac. Contraindicated in severe CKD. |
Aminoglycosides
Examples: Gentamicin, tobramycin, amikacin, streptomycin, neomycin
| Mechanism | Accumulate in renal proximal tubular cells → free radical generation → tubular cell necrosis → acute tubular necrosis (ATN). Effects are concentration-dependent and cumulative. |
| Risk Factors | Volume depletion, advanced age, pre-existing CKD, prolonged therapy (> 5 days), multiple daily dosing, concurrent vancomycin or furosemide, liver disease |
| Monitoring | Peak and trough levels (or AUC-based monitoring). Serum creatinine q2–3 days or daily if high risk. BUN. Urine output. Urine for casts (granular/muddy brown in ATN). Also ototoxic — monitor hearing and vestibular function. |
| Prevention | Extended-interval (once-daily) dosing reduces nephrotoxicity vs traditional dosing. Adequate pre-hydration. Avoid concurrent nephrotoxins. Shortest effective course. Monitor levels. |
| Nursing Notes | Draw trough BEFORE dose and peak 30–60 min AFTER dose (per institutional protocol). Report rising creatinine or falling urine output immediately. Ensure IV infusion over 30–60 min (NOT bolus). Monitor for ototoxicity (ringing in ears, vertigo, hearing loss). |
| NCLEX Pearl | Aminoglycosides: trough drawn BEFORE next dose; peak 30-60 min AFTER infusion. Monitor BUN/Cr and urine output. Ototoxic AND nephrotoxic. Extended-interval (q24h) dosing preferred. |
Iodinated Contrast Agents (CIN — Contrast-Induced Nephropathy)
Examples: IV iodinated contrast used in CT, cardiac catheterization, angiography; gadolinium for MRI (NSF risk in severe CKD)
| Mechanism | Direct tubular toxicity + renal vasoconstriction → tubular ischemia → AKI. Usually occurs 24–48h after contrast; peak creatinine at 3–5 days; typically resolves in 7–10 days. |
| Risk Factors | Pre-existing CKD (eGFR < 60 = significant risk; < 30 = high risk), diabetes mellitus, dehydration, large contrast volumes, multiple contrast exposures in short period, concurrent NSAIDs/nephrotoxins |
| Monitoring | Baseline BUN/Cr and eGFR before procedure. Creatinine at 24–48h post-contrast. Urine output post-procedure. |
| Prevention | IV normal saline hydration: 0.9% NS 1 mL/kg/hr for 3–12h before and 6–12h after (most evidence-based intervention). Use low-osmolality or iso-osmolality contrast. Minimize contrast volume. Avoid concurrent NSAIDs/nephrotoxins. N-acetylcysteine (controversial evidence — still used at some institutions: 600–1200 mg PO bid × 2 days). Hold metformin 48h after contrast if eGFR < 60 (risk of lactic acidosis if AKI occurs). |
| Nursing Notes | Confirm eGFR/creatinine before procedure. Ensure IV hydration is running pre-procedure. Hold metformin if ordered. Post-procedure: monitor urine output, creatinine. Ensure patient is not dehydrated before procedure. NPO policies must balance contrast-AKI risk. |
| NCLEX Pearl | IV saline hydration is the most effective CIN prevention. Hold metformin before/after contrast in CKD. Creatinine peaks 3–5 days post-contrast. Gadolinium causes NSF (nephrogenic systemic fibrosis) in severe CKD — avoid. |
ACE Inhibitors & ARBs
Examples: ACE-I: lisinopril, enalapril, ramipril, captopril. ARBs: losartan, valsartan, irbesartan, candesartan
| Mechanism | Block angiotensin II → efferent arteriole dilation → reduced intraglomerular pressure. Beneficial long-term (renoproctive) but acute GFR drop can occur. Dangerous when both afferent AND efferent vasodilation occur simultaneously (NSAIDs block afferent dilation + ACE/ARB blocks efferent constriction → catastrophic GFR loss). |
| Risk Factors | Volume depletion, concurrent NSAIDs or diuretics, bilateral renal artery stenosis (contraindication — depend on angiotensin II to maintain GFR), dehydration |
| Monitoring | Check creatinine and potassium 1–2 weeks after initiating and with dose increases. A creatinine rise up to 30% above baseline is acceptable (reflects hemodynamic effect, not structural damage). > 30% rise = hold and evaluate. Monitor for hyperkalemia. |
| Prevention | Ensure adequate hydration before initiation. Avoid concurrent NSAIDs. Avoid in bilateral renal artery stenosis. Use cautiously in severe CKD. |
| Nursing Notes | Teach patients not to stop ACE/ARBs without provider guidance. Monitor K+ (hyperkalemia risk). Monitor BP (hypotension increases AKI risk). ACE inhibitors cause dry cough (switch to ARB if cough). ACE inhibitors cause angioedema — emergency if tongue/throat swelling. |
| NCLEX Pearl | ACE inhibitor + bilateral renal artery stenosis = CONTRAINDICATED (acute AKI, life-threatening). Acceptable: creatinine rise up to 30% after initiating. > 30% = stop and report. Hyperkalemia is a known side effect. |
Vancomycin
Examples: Vancomycin IV (glycopeptide antibiotic for MRSA, Clostridioides difficile — IV only for systemic infections)
| Mechanism | Exact mechanism uncertain: oxidative stress, tubular toxicity, possibly immune-mediated. Nephrotoxicity greatly increased when combined with aminoglycosides, piperacillin-tazobactam, loop diuretics, or IV contrast. |
| Risk Factors | High trough levels (traditional monitoring), concurrent aminoglycosides or pip-tazo (particularly high-risk combination), prolonged therapy, CKD, volume depletion, ICU admission, obesity (larger doses) |
| Monitoring | AUC/MIC-based monitoring now preferred over traditional trough monitoring (target AUC 400–600 mg·h/L). Serum creatinine daily or q48h in high-risk patients. Urine output. |
| Prevention | AUC-based dosing rather than trough targets. Avoid or minimize concurrent aminoglycosides and piperacillin-tazobactam. Maintain hydration. Limit therapy duration. |
| Nursing Notes | Administer IV vancomycin over ≥ 60 minutes (1 gram) or longer for larger doses — rapid infusion causes Red Man Syndrome (histamine-release flushing/hypotension). Red Man Syndrome ≠ allergy — treated with slowing infusion rate. Monitor creatinine trends. Report rising creatinine to provider. |
| NCLEX Pearl | Vancomycin + aminoglycoside = very high nephrotoxicity risk. AUC monitoring is current standard. Red Man Syndrome (red flushing, hypotension) = slow the infusion, not an allergic reaction. |
Cisplatin (Platinum-Based Chemotherapy)
Examples: Cisplatin, carboplatin (less nephrotoxic), oxaliplatin
| Mechanism | Cisplatin accumulates in proximal tubular cells → DNA crosslinking → oxidative stress → tubular cell death (ATN pattern). Also causes hypomagnesemia (Mg wasting from tubular damage). |
| Risk Factors | Cumulative dose (dose-dependent toxicity), pre-existing CKD, volume depletion, concurrent nephrotoxins, repeated cycles |
| Monitoring | Creatinine and eGFR before each cycle. Electrolytes (Mg, K, Ca, phosphorus). Urine output. Cumulative dose tracking. |
| Prevention | Aggressive IV NS hydration before and after cisplatin (standard cisplatin protocol). Forced diuresis with mannitol or furosemide in some protocols. Amifostine (cytoprotectant — nephroprotective in some protocols). Adequate Mg replacement. |
| Nursing Notes | Administer pre-hydration exactly as ordered (typically 1–2L NS before cisplatin). Monitor urine output during infusion. Maintain UO > 100 mL/hr during cisplatin. Aggressively replace Mg post-cisplatin (cisplatin causes profound hypomagnesemia). Monitor for nephrotoxicity and ototoxicity (both are dose-limiting). |
| NCLEX Pearl | Cisplatin = nephrotoxic AND ototoxic. Pre-hydration and forced diuresis are essential. Causes hypomagnesemia (Mg replacement often required). Monitor creatinine before each cycle. |
Calcineurin Inhibitors (Transplant Immunosuppressants)
Examples: Tacrolimus (FK506, Prograf), Cyclosporine (Sandimmune, Neoral)
| Mechanism | Afferent arteriolar vasoconstriction → reduced GFR. Long-term: irreversible tubulointerstitial fibrosis (chronic calcineurin inhibitor nephropathy). Also directly tubulotoxic. |
| Risk Factors | High blood levels, dehydration, concurrent NSAIDs or ACE inhibitors, duration of use |
| Monitoring | Whole blood trough levels (tacrolimus: target 5–15 ng/mL; cyclosporine: varies by protocol). Creatinine q1–3 months. eGFR trends. BP (both drugs are hypertensive). |
| Prevention | Target minimum effective immunosuppressive levels. Avoid hypovolemia. Avoid concurrent nephrotoxins. Regular drug level monitoring. |
| Nursing Notes | Tacrolimus levels drawn as TROUGH (before morning dose). Teach patient to take tacrolimus at the same time each day (12h apart for twice-daily dosing). NEVER adjust dose without provider. Report creatinine rise or decreased urine output immediately — may signal rejection vs drug toxicity (biopsy differentiates). Both tacrolimus and cyclosporine cause HTN, hyperkalemia, hyperglycemia, neurotoxicity. |
| NCLEX Pearl | Tacrolimus trough drawn before AM dose. Calcineurin inhibitors cause HTN, hyperkalemia, nephrotoxicity, and neurotoxicity. Rising creatinine in transplant = rejection vs drug toxicity — requires biopsy. |
Universal AKI Prevention Principles
| Maintain hydration | Adequate intravascular volume is the single most important protective factor. Ensure pre-hydration before contrast, aminoglycosides, cisplatin. Encourage PO fluids in high-risk patients. |
| Avoid nephrotoxin combinations | Never combine: aminoglycoside + vancomycin (very high risk). Avoid: NSAIDs + ACE inhibitor + diuretic ("triple whammy" AKI). Avoid: aminoglycosides + furosemide + cisplatin. |
| Monitor early | Daily BUN/Cr in high-risk patients. Urine output monitoring. Any creatinine rise > 0.3 mg/dL within 48h = KDIGO Stage 1 AKI — act early. |
| Report promptly | Rising creatinine, decreasing UO (< 0.5 mL/kg/hr), or supratherapeutic drug levels should be communicated to the provider immediately. |
| Review MAR for risk | Before administering potentially nephrotoxic medications, review: current eGFR/creatinine, current hydration status, concurrent nephrotoxins, patient's baseline CKD status. |
NCLEX Pearls
"Triple whammy" AKI: NSAID + ACE inhibitor + diuretic = additive AKI risk. Report this combination to provider.
Aminoglycoside monitoring: trough drawn BEFORE dose; peak 30–60 min AFTER infusion. Extended-interval dosing (q24h) reduces nephrotoxicity.
IV hydration = most evidence-based CIN prevention. N-acetylcysteine is controversial. Hold metformin before contrast if eGFR < 60.
Vancomycin Red Man Syndrome ≠ allergy — slow the infusion rate. But true allergy (urticaria, bronchospasm, anaphylaxis) IS an allergy.
Cisplatin = aggressive pre-hydration + Mg replacement. Both nephrotoxic and ototoxic.
ACE/ARB + bilateral renal artery stenosis = CONTRAINDICATED.
Tacrolimus trough = before morning dose. Rising creatinine in transplant patient = contact provider immediately (rejection vs toxicity).
Related Resources
Standards & sources
Fact-checked Jun 21, 2026This page is written to align with KDIGO Clinical Practice Guidelines · National Kidney Foundation (NKF). It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →